

Basic Policy on Business Continuity Management

1. Purpose of Business Continuity Management

As part of our business continuity management (“BCM”), to prepare for various risks that may hinder business continuity, such as large-scale earthquakes, floods, and other natural disasters, man-made disasters such as large-scale fires and riots, and plant closures due to pandemics such as new strains of the influenza virus and coronavirus, we establish a BCM system to ensure rapid restoration of business operations and swift responses to customers, while giving top priority to respect for human life. With this system, we strive to meet the needs of our stakeholders.

- (a) In the event of a large-scale disaster, we will place top priority on ensuring the safety of our employees, their families, local residents, and others.
- (b) Even in the event of a large-scale disaster, we will strive to stably supply our products while also ensuring, to the extent possible, the operation of systems to provide, collect, and communicate drug information.
- (c) We will contribute to local communities through support for reconstruction of disaster-stricken areas.

2. Scope of BCM

We treat all risks that may hinder business continuity as subject to BCM. Based on factors such as the likelihood of their occurrence and their impact on management, we make a comprehensive evaluation of the degree of urgency and implement countermeasures, starting with the most urgent.

3. Composition of BCM

In accordance with this Policy, we build the BCM system based on internal rules, manuals specifying business continuity plans, and other materials.

4. Establishment of a Structure for Effective BCM Operation

We regularly conduct education and training to ensure compliance and thorough implementation of rules and manuals developed in accordance with this Policy, as well as related laws, regulations, and social norms. We implement appropriate measures to enhance the effectiveness of BCM by checking the implementation status of education and training and the development status of BCM and considering improvement measures.

October 1, 2022

Kissei Pharmaceutical Co., Ltd.